Glucagon like peptide 1 receptor: mechanisms and advances in therapy Signal Transduction and Targeted Therapy Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity Diabetes Therapy Springer Nature Link Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Long acting amylin related peptides as therapies for obesity and type 2 diabetes ScienceDirect New Developments in Pharmacological Treatment of Obesity and Type 2 DiabetesBeyond and within GLP 1 Receptor Agonists CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current